Abbott Laboratories branding.
(Bloomberg) — Abbott Laboratories raised the lower end of its annual profit forecast as strong sales in medical devices drove first-quarter earnings and revenue above expectations.
Adjusted earnings for the year will be in the range of $4.55 to $4.70 a share, the company said Wednesday in a statement. The earlier guidance was for $4.50 to $4.70 a share. Profit for the quarter was 98 cents a share, while analysts had estimated 95 cents.
Quarterly revenue of $10 billion narrowly beat Street projections.
Sales of Abbott’s continuous glucose monitors were $1.5 billion for the quarter, while analysts had foreseen $1.45 billion. The market for CGMs, which measure blood glucose levels at regular intervals, is seen as reaching $12 billion in patients with diabetes who use insulin, according to Bloomberg Intelligence.
Abbott Laboratories branding.
The shares fell 0.8% in trading before US markets opened.
Most Read from Bloomberg
©2024 Bloomberg L.P.
News Related-
AWS and Clarity AI to use generative AI to boost sustainable investments
-
Ref Watch: 'Enough' of a foul to disallow Man City goal vs Liverpool
-
Day in the Life: Ex-England rugby star on organising this year's Emirates Dubai Sevens
-
Pandya returns to MI, Green goes to RCB
-
Snowstorm kills eight in Ukraine and Moldova, hundreds of towns lose power
-
‘This is why fewer Sikhs visiting gurdwaras abroad’: BJP after Indian envoy heckled in Long Island
-
Inside a Dubai home with upcycled furniture and zero waste
-
Captain Turner aims for Pitch 1 return as JESS bid to retain Dubai Sevens U19 crown
-
No Antoine Dupont but Dubai still set to launch new era for sevens
-
Why ESG investors are concerned about AI
-
Your campsite can harm the environment
-
Mubadala, Saudi Fund deals on US radar for potential China angle
-
Abu Dhabi T10 season seven to kick off with thrilling double-header
-
Eight climate fiction, or cli-fi, books to consider before Cop28